Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02120300
Other study ID # GS-US-334-1274
Secondary ID
Status Completed
Phase Phase 2
First received April 18, 2014
Last updated August 25, 2015
Start date April 2014
Est. completion date August 2015

Study information

Verified date August 2015
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will evaluate the antiviral efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for participants with genotypes 1 and 4 hepatitis C virus (HCV) infection and sofosbuvir (SOF) plus ribavirin (RBV) for participants with genotypes 2 and 3 HCV infection. Participants with an inherited bleeding disorder and chronic HCV infection (either monoinfected or HIV-1/HCV coinfected) will be enrolled.


Recruitment information / eligibility

Status Completed
Enrollment 122
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Hemophilia A, B or C, or Von Willebrand's disease

- Chronic genotype 1, 2, 3 or 4 HCV infection

- HCV RNA = 1000 IU/mL at screening

- Use of protocol specified method(s) of contraception if female of childbearing potential or sexually active male

- Screening laboratory values within defined thresholds

- For HIV-1/HCV co-infected participants:

- Suppressed HIV-1 RNA on an antiretroviral (ARV) regimen for at least 6 months prior to screening

- Stable protocol-approved ARV regimen for > 8 weeks prior to screening

- CD4 T-cell count > 200 cells/mm^3 at screening

Exclusion Criteria:

- Clinically-significant illness (other than HCV, inherited bleeding disorder or HIV-1) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Current or prior history of any of the following:

- Hepatic decompensation

- Chronic liver disease of a non-HCV etiology

- Hepatocellular carcinoma (HCC)

- Infection with hepatitis B virus (HBV)

- Pregnant or nursing female

- Prior treatment with inhibitors of NS5A or the NS5B polymerase

- Chronic use of systemically administered immunosuppressive agents

- For HIV-1/HCV co-infected subjects:

- Opportunistic infection within 6 months prior to screening

- Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
LDV/SOF
Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally
SOF
Sofosbuvir (SOF) 400 mg tablet administered orally once daily
RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and = 75 kg = 1200 mg)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12) SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug. Posttreatment Week 12 No
Primary Incidence of adverse events leading to permanent discontinuation of study drug(s) Up to 24 weeks No
Secondary Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4) SVR4 is defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug. Posttreatment Week 4 No
Secondary Proportion of participants with HCV RNA < LLOQ on treatment Up to 24 weeks No
Secondary HCV RNA change from baseline Up to 24 weeks No
Secondary Proportion of participants with virologic failure Virologic failure is defined as:
Breakthrough: HCV RNA = LLOQ after having previously had HCV RNA < LLOQ, while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values, OR
Rebound: > 1 log10IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values, OR
Nonresponse: HCV RNA persistently = LLOQ through 8 weeks of treatment, OR
Relapse: HCV RNA = LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement
Up to Posttreatment Week 12 No
Secondary For HIV-1/HCV co-infected participants, the proportion of participants that maintain HIV-1 RNA < 50 copies/mL while on HCV treatment Up to 24 weeks No
Secondary For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at the end of treatment Up to 24 weeks No
Secondary For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at posttreatment Week 12 Up to Posttreatment Week 12 No
See also
  Status Clinical Trial Phase
Completed NCT01938430 - Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant Phase 2
Completed NCT01984294 - Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection Phase 2
Completed NCT01975675 - Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection Phase 3
Completed NCT02074514 - Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection Phase 3
Recruiting NCT05395416 - Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C Phase 2/Phase 3
Completed NCT03458481 - Phase 2 Study of Yimitasvir Phosphate Capsules Phase 2
Completed NCT02010255 - Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant Phase 2
Recruiting NCT00842205 - Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection N/A
Completed NCT02973503 - Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis Phase 3
Recruiting NCT03540212 - Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus Phase 2/Phase 3
Completed NCT02021643 - Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection Phase 3
Completed NCT02021656 - Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection Phase 3
Completed NCT03487107 - Phase 3 Study of Yimitasvir Phosphate Capsules Phase 3